<DOC>
	<DOCNO>NCT00876850</DOCNO>
	<brief_summary>A Phase III trial demonstrate safety efficacy PTK 0796 treatment complicate skin skin structure infection ( cSSSI ) .</brief_summary>
	<brief_title>Phase 3 Study - Safety Efficacy PTK 0796 Patients With Complicated Skin Skin Structure Infection ( CSSSI )</brief_title>
	<detailed_description>The pharmacologic profile PTK 0796 human suggest potential use safely effectively indication . Data vitro animal study support hypothesis . In PTK 0796-CSSI-0805 safety efficacy PTK 0796 treatment cSSSI compare antibiotic approve indication FDA . Initial treatment administer intravenously option subsequent oral treatment .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Soft Tissue Infections</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<criteria>Has acute complicate skin skin structure infection finding systemic inflammatory response Patients , age 18 year old Is expect require great equal 4 day antibiotic therapy Female patient must pregnant time enrollment must agree reliable method birth control study 30 day follow last dose study drug Has receive investigational drug within past 1 month Has previously enrol protocol Has receive &gt; 48hr potentially effective systemic antibiotic immediately prior study drug Is nurse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>cSSI</keyword>
	<keyword>Abscess</keyword>
	<keyword>Would</keyword>
	<keyword>Cellulitis</keyword>
	<keyword>Complicated Skin Skin Structure Infections ( cSSSI )</keyword>
</DOC>